12:00 AM
 | 
Mar 04, 2002
 |  BioCentury  |  Product Development

Paclitaxel not without limits

Beyond its role as a cancer agent, researchers believe paclitaxel has potential to treat a variety of autoimmune and inflammatory disorders based on its inhibition of the AP-1 transcription factor. However, the prospects of the compound in such areas may be limited. Last week, Angiotech Pharmaceuticals Inc. decided to end development of its Paxceed micellar formulation in multiple sclerosis, although the company said it will continue clinical testing in...

Read the full 331 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >